<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02581163</url>
  </required_header>
  <id_info>
    <org_study_id>P15-650</org_study_id>
    <nct_id>NCT02581163</nct_id>
  </id_info>
  <brief_title>Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, +/- Dasabuvir, +/- Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium</brief_title>
  <official_title>Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, +/- Dasabuvir, +/- Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IST GmbH, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to provide evidence of the effectiveness as well as the influence of adherence
      on treatment outcome of Paritaprevir/ritonavir, Ombitasvir, +/- Dasabuvir, (the ABBVIE
      REGIMEN) ± Ribavirin (RBV) in a real world setting of hepatitis C virus infected clinical
      practice populations across Belgium. The study may also help identify predictive factors of
      response that are important in real world treatment settings. In addition, it will provide
      data on the impact of adherence on treatment outcomes in everyday settings, which may help
      treating physicians to improve the management of participants under their care.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 7, 2015</start_date>
  <completion_date type="Actual">February 9, 2018</completion_date>
  <primary_completion_date type="Actual">February 9, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants achieving sustained virological response at week 12 (SVR12)</measure>
    <time_frame>12 weeks after the last dose of study drug</time_frame>
    <description>SVR12 is defined as hepatitis c virus ribonucleic acid levels &lt;50 IU/mL 12 weeks after the last dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients meeting Premature study drug discontinuation with no on-treatment virologic failure</measure>
    <time_frame>12 weeks after last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients missing SVR12 data and/or none of the criteria below: -on-treatment virologic failure or failure to suppress -relapse -premature study drug discontinuation with no on-treatment virologic failure</measure>
    <time_frame>12 weeks after last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients meeting relapse</measure>
    <time_frame>12 weeks after last dose of study drug</time_frame>
    <description>Relapse : defined as HCV RNA &lt;50 IU/mL at EoT or at the last on-treatment HCV RNA measurement followed by HCV RNA ≥50 IU/mL post-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who achieved breakthrough</measure>
    <time_frame>From baseline till End of treatment: 12 or 24 weeks after first dose according to treatment schedule chosen by investigator</time_frame>
    <description>Breakthrough is defined as at least one documented HCV RNA &lt;50 IU/ml followed by HCV RNA ≥ 50 IU/ml during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients meeting On-treatment virologic failure</measure>
    <time_frame>12 weeks after last dose of study drug</time_frame>
    <description>On-treatment virologic failure : breakthrough or failure to suppress [each measured on-treatment HCV RNA value ≥50 IU/mL]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with virological response.</measure>
    <time_frame>End of treatment (EoT), 12 or 24 weeks after first dose according to treatment schedule chosen by investigator.</time_frame>
    <description>Virologic response is defined as HCV RNA &lt;50 IU/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who relapse</measure>
    <time_frame>At 12 and 24 weeks after last dose of study drug</time_frame>
    <description>Relapse is defined as HCV RNA &lt; 50 IU/ml at end of treatment followed by HCV RNA ≥ 50 IU/ml</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of the DAA dose taken in relation to the target dose of DAA</measure>
    <time_frame>From Baseline till EoT (12 or 24 weeks after first dose according to treatment schedule chosen by investigator)</time_frame>
    <description>Adherence : cumulative dose taken divided by target dose in percent</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of missed RBV treatment days in relation to the target number of RBV treatment days</measure>
    <time_frame>From Baseline till EoT (12 or 24 weeks after first dose according to treatment schedule chosen by investigator)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of the RBV dose taken in relation to the target dose of RBV</measure>
    <time_frame>From Baseline till EoT (12 or 24 weeks after first dose according to treatment schedule chosen by investigator)</time_frame>
    <description>Adherence : cumulative dose taken divided by target dose in percent</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">309</enrollment>
  <condition>Chronic Hepatitis C, Genotype 1 or 4</condition>
  <arm_group>
    <arm_group_label>GT 1 or 4 treatment-naïve or -experienced CHC participants</arm_group_label>
    <description>Treatment-naïve or -experienced participants with confirmed CHC, genotype (GT) 1 or 4, receiving combination therapy with the interferon-free ABBVIE REGIMEN ± RBV according to standard of care and in line with the current local label</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Treatment-naïve or -experienced participants with confirmed CHC, genotype 1 or 4
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment-naïve or -experienced participants with confirmed CHC, genotype 1 or 4,
             receiving combination therapy with the interferon-free ABBVIE REGIMEN ± RBV according
             to standard of care and in line with the current local label

          -  If RBV is co-administered with the ABBVIE REGIMEN, it has been prescribed in line with
             the current local label (with special attention to contraception requirements and
             contraindication during pregnancy)

          -  Participants must sign and date an informed consent

        Exclusion Criteria:

          -  Participant participating or intending to participate in a concurrent interventional
             therapeutic trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CUB Hospital Erasme</name>
      <address>
        <city>Brussels</city>
        <state>Bruxelles-Capitale</state>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc</name>
      <address>
        <city>Woluwe-Saint-Lambert</city>
        <state>Bruxelles-Capitale</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Hôpital de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <state>Hainaut</state>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Liege - Domain Universi</name>
      <address>
        <city>Liège</city>
        <state>Liege</state>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algemeen Stedelijk Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <state>Oost-Vlaanderen</state>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Wallonie Picarde</name>
      <address>
        <city>Tournai</city>
        <state>Wallonne, Region</state>
        <zip>7500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZNA Stuivenberg</name>
      <address>
        <city>Antwerp</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU St. Pierre</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HIS - Bracops</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Edith Cavell</name>
      <address>
        <city>Brussels</city>
        <zip>1180</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HIS Moliere-Longchamp</name>
      <address>
        <city>Brussels</city>
        <zip>1190</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Antwerp</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Z.O.L - Campus St. Jan</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique St Joseph</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U.de Mons Borinage</name>
      <address>
        <city>Mons</city>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ-Delta</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL Mont Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com</url>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2015</study_first_submitted>
  <study_first_submitted_qc>October 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2015</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Effectiveness</keyword>
  <keyword>Influence of adherence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

